Carcinogenicity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
ArNH2 + HNO2 → [ArNN]Cl + 2 H2O Nitrite is also a common ligand that can coordinate in five ways. The most common are nitro (bonded from the nitrogen) and nitrito (bonded from an oxygen). Nitro-nitrito isomerism is common, where the nitrito form is usually less stable.
On the day that it was inaugurated, two floors were being rented-out to businesses unrelated to Freemasonry. The tenth floor acted as the law offices of the law firm owned by the Grand Master, and to avoid commingling, when he needed to do business as a lawyer, he would sit in his office on the tenth floor, but when he needed to act as the Grand Master, he would walk upstairs to the Office of the Grand Master.
They often show dilated endoplasmic reticulum, numerous vesicular bodies, and a lack of microtubular structure in transmission electron microscopy study. Therefore, interpretation of these observations would be that despite high protein production and protein turnover in diabetic ulcer fibroblasts, vesicles containing secretory proteins could not travel along the microtubules to release the products outside. Fibroblasts from diabetic ulcer exhibit proliferative impairment that probably contributes to a decreased production of extracellular matrix proteins and delayed wound contraction and impaired wound healing. Increased matrix metalloproteinases (MMP) activity For a wound to heal, extracellular matrix not only needs to be laid down but also must be able to undergo degradation and remodeling to form a mature tissue with appropriate tensile strength. Proteases, namely matrix metalloproteinases are known to degrade almost all the extracellular matrix components. They are known to be involved in fibroblast and keratinocyte migration, tissue reorganization, inflammation, and remodeling of the wounded tissue. Due to persistently high concentrations of pro-inflammatory cytokines in diabetic ulcers, MMP activity is known to increase by 30 fold when compared to acute wound healing. MMP-2 and MMP-9 show sustained overexpression in chronic non-healing diabetic ulcers. Balance in the MMP activity is usually achieved by tissue inhibitor of metalloproteinases (TIMP).
=== Infusions === There are many varieties of cannabis infusions owing to the variety of non-volatile solvents used. The plant material is mixed with the solvent and then pressed and filtered to express the oils of the plant into the solvent. Examples of solvents used in this process are cocoa butter, dairy butter, cooking oil, glycerine, and skin moisturizers. Depending on the solvent, these may be used in cannabis foods or applied topically.
Sources: en.wikipedia.org
== Education and career == Okamoto received his B.S. (1964), M.S. (1966), and Ph.D. (1969) degrees from Osaka University, and served as assistant professor and associate professor at the university from 1969 to 1990. In 1990 he became a professor at Nagoya University. After retiring in 2004, he was appointed Guest Professor of EcoTopia Science Institute, Nagoya University. He was appointed as Chair Professor of Harbin Engineering University in 2007.
=== Phosphoenolpyruvate carboxykinase (PEPC-K) === Glyceroneogenesis can be regulated at two reaction pathways. First, it can be held at the decarboxylation of oxaloacetate to phosphoenolpyruvate. Secondly, the TCA cycle can affect glyceroneogenesis when the glutamate or substrates in the TCA cycle are being used as a precursor. Decarboxylation of oxaloacetate to phosphoenolpyruvate is catalyzed by PEPC-K, the essential enzyme which regulates glyceroneogenesis. Increases in PEPC-K levels or overexpression of the gene that codes for PEPC-K will increase glyceroneogenesis. Also, oxaloacetate can be decarboxylated to phosphoenolpyruvate when more PEPC-K can catalyze the reaction. Gene expression of PEPC-K can be suppressed by norepinephrine, glucocorticoids, and insulin. Norepinephrine is a neurotransmitter which decreases the activity of PEPC-K when the cell is in a cold environment. Glucocorticoids are steroid hormones involved in the reciprocal regulation of glyceroneogenesis in the liver and adipose tissues. Through a poorly-understood mechanism, they induce transcription of PEPC-K in the liver while decreasing transcription in adipose tissues. Insulin is a peptide hormone that causes cells to take in glucose. Through glyceroneogenesis, insulin down-regulates the expression of PEPC-K in both liver and adipose tissues.
Reconnecting after years of estrangement, Enric and Irene confront their abusive past — discovering their father Albert lived a separate wealthy life and that Montserrat has continued her delusional cult. Enric infiltrates the family home during Christmas, exposing Montserrat’s lies, which culminates in Cecilia fleeing the household to join Irene. Following a visionary ayahuasca trip where Enric finally processes his childhood trauma while Irene and Cecilia rebuild their lives.
Tarlov concluded that such cysts, though often overlooked during standard imaging or surgery, could produce clinically significant symptoms and should be considered in cases of unexplained sciatic pain. He published these findings in the paper "Cysts (Perineurial) of the Sacral Roots: Another Cause (Removable) of Sciatic Pain" (1948). In 1952, Tarlov published his third paper on perineurial cysts, titled "Cysts of the Sacral Nerve Roots: Clinical Significance and Pathogenesis". In this work, he acknowledged the limitations of his earlier cadaver studies due to incomplete medical records, noting that the symptomatic relevance of the cysts was initially unclear. The paper presented detailed accounts of two surgical cases from 1950 and 1951 in which sacral nerve root cysts were associated with neurological symptoms. The first patient, a 28-year-old man with progressive numbness, urinary incontinence, and sexual dysfunction, was found to have bilateral S2 cysts; surgical removal of the right cyst and drainage of the left halted symptom progression and improved bladder function. The second case involved a 70-year-old woman with paresthesia in the right leg and vaginal area, foot weakness, and sacral tenderness, in whom four cysts were discovered on the S2 and S3 nerve roots. Partial excision led to improvement in foot strength and partial symptom relief. Tarlov also discussed two post-mortem cases in which subarachnoid hemorrhages and sacral cysts coexisted, prompting the hypothesis that the cysts might occasionally form secondary to hemorrhagic damage to nerve roots.
==== Combination drugs ==== Butalbital/acetaminophen (Butapap) – combination of butalbital (GABAA receptor positive allosteric modulator and barbiturate) and acetaminophen (analgesic) Ergotamine/caffeine (Cafergot) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline) and caffeine (adenosine receptor antagonist) Ergotamine/chlorcyclizine/caffeine (Anervan) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline), chlorcyclizine (antihistamine and other actions), and caffeine (adenosine receptor antagonist) Meloxicam/rizatriptan (AXS-07; Symbravo) – combination of meloxicam (COX inhibitor/NSAID) and rizatriptan (triptan) [139] Naproxen sodium/sumatriptan (MT-400; SumaRT/Nap; Suvexx; Trexima; Treximet) – combination of naproxen (COX inhibitor/NSAID) and sumatriptan (triptan) – migraine [140] Paracetamol/codeine/buclizine (Migraleve Yellow) – combination of paracetamol (analgesic) and codeine (opioid) Paracetamol/codeine/buclizine (Migraleve Pink) – combination of paracetamol (analgesic), codeine (opioid), and buclizine (antihistamine and other actions) Paracetamol/dichloralphenazone/isometheptene (Amidrine) – combination of paracetamol (analgesic), dichloralphenazone (phenazone (COX inhibitor/NSAID) and chloral hydrate (GABAA receptor positive allosteric modulator)), and isometheptene (adrenergic receptor agonist) Paracetamol/metoclopramide (Paramax) – combination of paracetamol (analgesic) and metoclopramide (various actions) Sumatriptan/naproxen (Treximet) – combination of sumatriptan (triptan) and naproxen (COX inhibitor/NSAID)
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.